Lung cancer is one of the leading causes of cancer-related deaths worldwide. It refers to malignant tumors that occur in the lungs and is mainly divided into two major categories:

• Non–small cell lung cancer (NSCLC): the most common type, including adenocarcinoma, squamous cell carcinoma, and other subtypes.
• Small cell lung cancer (SCLC): relatively rare, but grows and spreads more rapidly.

Identifying the correct category and subtype is essential for determining the optimal treatment strategy.

Common Symptoms

Early-stage lung cancer may present no obvious discomfort. As the disease progresses, patients may experience:

• Persistent cough or worsening of an existing cough
• Recurrent respiratory infections
• Coughing up blood or blood-streaked sputum
• Chest pain or pain when coughing
• Shortness of breath, fatigue, loss of appetite, and weight loss

Some patients may also develop hoarseness, difficulty swallowing, swelling in the face or neck, or clubbing of fingers and toes. If any of these symptoms occur, medical evaluation is recommended.

Diagnosis and Staging

A confirmed diagnosis of lung cancer usually requires a combination of tests. Imaging tests such as contrast-enhanced chest CT or PET-CT help assess the tumor’s size, location, lymph node involvement, and distant metastasis. Pathological examination—via bronchoscopy, percutaneous biopsy, or surgical sampling—is the gold standard for diagnosis and determines the tumor’s histological type.

Molecular profiling and immunological testing (e.g., EGFR/ALK mutations, PD-L1 expression) are also performed to guide targeted therapy and immunotherapy options.
Doctors will additionally assess disease stage in order to design a more precise and personalized treatment plan.

Surgery

Primarily used for early-stage or localized lung cancer and is the preferred curative approach.

Radiotherapy

Suitable for patients who cannot undergo surgery, or for those with locally advanced disease or requiring symptom control. Precision radiotherapy can achieve surgery-like outcomes in selected early-stage cases.

Chemotherapy

A systemic treatment widely used as perioperative therapy, for locally advanced disease, or metastatic disease control. It remains a cornerstone of lung cancer management.

Targeted Therapy

For patients with specific driver gene mutations such as EGFR, ALK, ROS1, or HER2, targeted drugs can precisely inhibit tumor pathways and significantly improve outcomes and survival.

Immunotherapy

Immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) restore the immune system’s ability to recognize and attack cancer cells and are important options for advanced or locally advanced disease.

The lung cancer expert team at GoBroad Healthcare Group (GoBroad) has extensive clinical and translational research experience. We are committed to aligning diagnosis and treatment with international standards, rapidly transforming scientific advances into clinical practice, and helping patients achieve longer survival and better quality of life. We focus not only on treating the disease, but also on comprehensive care throughout the patient journey.

The GoBroad lung cancer team has long been dedicated to advancing lung cancer treatment. We lead the development and clinical translation of innovative medicines, contributing to the approval of several new drugs in China. We also participate deeply in international multicenter research, allowing Chinese patients to benefit from global-synchronized therapies.

Additionally, our experts play key roles in drafting and updating authoritative guidelines and consensus statements, providing scientific and standardized references for clinical practice and continuously elevating the standard of lung cancer care in China.

These efforts not only strengthen GoBroad’s academic leadership in lung cancer but, more importantly, help patients achieve longer survival and better quality of life. GoBroad remains committed to enabling patients in China to access world-class, cutting-edge treatments.

The efficacy data are derived from published studies and GoBroad Healthcare Group’s long-term follow-up results. For medical reference only. Individual outcomes may vary depending on disease type and treatment plan. Please consult with a qualified physician for a personalized treatment strategy.